SCHEMBL4473146

SCHEMBL4473146

COc1cc2c(Oc3ccc(Nc4ccc(C(C)(C)C)cc4)cc3)ccnc2cc1OCCCN1CCN(C)CC1

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR2 P21802 15/20 0.87
PDGFRB P09619 1/20 0.67
KIT P10721 1/20 0.67
PDGFRA P16234 1/20 0.67
KDR P35968 1/20 0.67
AXL P30530 5/20 0.57
PLK4 O00444 1/20 0.56
AURKA O14965 1/20 0.56
GAK O14976 1/20 0.56
RIPK2 O43353 1/20 0.56
PRKAB2 O43741 1/20 0.56
ERN1 O75460 1/20 0.56
STK10 O94804 1/20 0.56
MAP4K4 O95819 1/20 0.56
EGFR P00533 1/20 0.56
FYN P06241 1/20 0.56
YES1 P07947 1/20 0.56
LYN P07948 1/20 0.56
MET P08581 1/20 0.56
SRC P12931 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4484976 0.97 FGFR2 (0.83) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4473572 0.96 FGFR2 (0.84) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4479490 0.94 FGFR2 (0.98) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4478491 0.93 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4471592 0.93 FGFR2 (1.00) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL13936676 0.93 FGFR2 (0.81) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4476247 0.92 FGFR2 (0.92) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4487243 0.91 FGFR2 (0.95) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4464922 0.90 FGFR2 (0.82) FGFR2PDGFRBKITPDGFRAKDR
SCHEMBL4469764 0.90 FGFR2 (0.90) FGFR2PDGFRBKITPDGFRAKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US claimed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-7495104-B2 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2009-02-24 US disclosed
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors KIRIN BEER KABUSHIKI KAISHA (JP) 2005-03-03 US disclosed
EP-1447405-A1 QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING AUTO-PHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS KIRIN BEER KABUSHIKI KAISHA (JP) 2004-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049264-A1 Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors FGFR1, FGFR2, FGFR3 FGFR2 2/4885PDGFRB 202/4885KIT 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.